Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
porphyrias
Biotech
Alnylam’s givosiran hits the mark in phase 3 porphyria test
Alnylam's givosiran reduced the rate of porphyria attacks in patients with acute hepatic porphyria. The company will file a rolling NDA for givosiran in mid-2019.
Amirah Al Idrus
Mar 6, 2019 11:08am
Alnylam drops early filing plan for porphyria drug givosiran
Oct 15, 2018 10:05am
Alnylam heads for phase 3 with acute porphyria program
Jun 26, 2017 10:25am